Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2018 Nov 21. pii: S0924-8579(18)30332-7. doi: 10.1016/j.ijantimicag.2018.11.007. [Epub ahead of print]

2.

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-nonsusceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2018 Oct 25. pii: S0924-8579(18)30299-1. doi: 10.1016/j.ijantimicag.2018.10.007. [Epub ahead of print]

3.

Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.

Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1481-1489. doi: 10.1007/s10096-018-3274-y. Epub 2018 May 12.

PMID:
29754209
4.

Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae.

Hackel MA, Iaconis JP, Karlowsky JA, Sahm DF.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01892-17. doi: 10.1128/JCM.01892-17. Print 2018 Apr.

6.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01968-17. doi: 10.1128/AAC.01968-17. Print 2018 Feb.

7.

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01904-17. doi: 10.1128/AAC.01904-17. Print 2018 Jan.

8.

In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.

Karlowsky JA, Hackel MA, Bouchillon SK, Alder J, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Oct;89(2):151-157. doi: 10.1016/j.diagmicrobio.2017.07.001. Epub 2017 Jul 8.

PMID:
28793964
9.

Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide.

Hackel MA, Karlowsky JA, Dressel D, Sahm DF.

J Clin Microbiol. 2017 Oct;55(10):3021-3027. doi: 10.1128/JCM.00972-17. Epub 2017 Jul 26.

10.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00472-17. doi: 10.1128/AAC.00472-17. Print 2017 Sep.

11.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00093-17. doi: 10.1128/AAC.00093-17. Print 2017 Sep.

12.

Multicenter Performance Assessment of Carba NP Test.

Cunningham SA, Limbago B, Traczewski M, Anderson K, Hackel M, Hindler J, Sahm D, Alyanak E, Lawsin A, Gulvik CA, de Man TJB, Mandrekar JN, Schuetz AN, Jenkins S, Humphries R, Palavecino E, Vasoo S, Patel R.

J Clin Microbiol. 2017 Jun;55(6):1954-1960. doi: 10.1128/JCM.00244-17. Epub 2017 Apr 12.

13.

Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

Braz J Infect Dis. 2017 May - Jun;21(3):343-348. doi: 10.1016/j.bjid.2017.03.006. Epub 2017 Apr 8.

14.

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02209-16. doi: 10.1128/AAC.02209-16. Print 2017 Jun.

15.

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2.

PMID:
28291628
17.

Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens.

Grossman TH, Fyfe C, O'Brien W, Hackel M, Minyard MB, Waites KB, Dubois J, Murphy TM, Slee AM, Weiss WJ, Sutcliffe JA.

mSphere. 2017 Feb 22;2(1). pii: e00004-17. doi: 10.1128/mSphere.00004-17. eCollection 2017 Jan-Feb.

18.

Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

J Med Microbiol. 2017 Jan;66(1):61-69. doi: 10.1099/jmm.0.000421. Epub 2017 Feb 22.

PMID:
28051952
19.

In vitro activity of tigecycline against molecularly characterised strains of Enterobacteriaceae isolated from phase 3 clinical trials and the Tigecycline Evaluation and Surveillance Trial (TEST).

Biedenbach DJ, Hackel MA, Quintana A, Wible M, Dowzicky MJ, McGovern PC, Bouchillon SK.

J Glob Antimicrob Resist. 2015 Dec;3(4):311-312. doi: 10.1016/j.jgar.2015.09.004. Epub 2015 Oct 22. No abstract available.

PMID:
27842883
20.

Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology.

Hastey CJ, Boyd H, Schuetz AN, Anderson K, Citron DM, Dzink-Fox J, Hackel M, Hecht DW, Jacobus NV, Jenkins SG, Karlsson M, Knapp CC, Koeth LM, Wexler H, Roe-Carpenter DE; From the Ad Hoc Working Group on Antimicrobial Susceptibility Testing of Anaerobic Bacteria of CLSI.

Anaerobe. 2016 Dec;42:27-30. doi: 10.1016/j.anaerobe.2016.07.003. Epub 2016 Jul 15.

PMID:
27427465
22.

Two new species of Microcosmodes Strand (Coleoptera: Carabidae: Panagaenini) from Oman and Iran.

Häckel M, Azadbakhsh S.

Zootaxa. 2016 Jul 13;4137(4):553-60. doi: 10.11646/zootaxa.4137.4.7.

PMID:
27470744
23.

In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF.

Diagn Microbiol Infect Dis. 2016 Oct;86(2):194-9. doi: 10.1016/j.diagmicrobio.2016.07.012. Epub 2016 Jul 14.

PMID:
27461798
25.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.

Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4677-83. doi: 10.1128/AAC.02841-15. Print 2016 Aug.

26.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500. doi: 10.1128/AAC.00107-16. Print 2016 Aug.

27.

Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe-SMART 2011-2014.

Lob SH, Badal RE, Hackel MA, Sahm DF.

J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):72-79. doi: 10.1093/jpids/piv109.

PMID:
26883618
28.

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. doi: 10.1128/AAC.02820-15.

30.

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.

Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1385-92. doi: 10.1128/AAC.01870-15.

31.

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.

Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1067-78. doi: 10.1128/AAC.02379-15. Print 2016 Feb.

32.

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.

33.

Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends.

Kazmierczak KM, Lob SH, Hoban DJ, Hackel MA, Badal RE, Bouchillon SK.

Diagn Microbiol Infect Dis. 2015 Jul;82(3):209-14. doi: 10.1016/j.diagmicrobio.2015.03.025. Epub 2015 Apr 9.

PMID:
25956930
34.

Two new Craspedophorus species (Coleoptera: Carabidae: Panagaeini) from the Philippines.

Häckel M, Anichtchenko A.

Zootaxa. 2015 May 5;3955(3):427-34. doi: 10.11646/zootaxa.3955.3.9.

PMID:
25947863
35.

Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.

Hackel MA, Badal RE, Bouchillon SK, Biedenbach DJ, Hoban DJ.

Surg Infect (Larchmt). 2015 Jun;16(3):298-304. doi: 10.1089/sur.2014.060. Epub 2015 Apr 20.

PMID:
25894976
36.

Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013.

Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF.

Antimicrob Agents Chemother. 2015;59(6):3606-10. doi: 10.1128/AAC.05186-14. Epub 2015 Mar 23.

37.

Dissemination of NDM metallo-β-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012.

Biedenbach D, Bouchillon S, Hackel M, Hoban D, Kazmierczak K, Hawser S, Badal R.

Antimicrob Agents Chemother. 2015 Feb;59(2):826-30. doi: 10.1128/AAC.03938-14. Epub 2014 Nov 17.

38.

Global incidence of carbapenemase-producing Escherichia coli ST131.

Peirano G, Bradford PA, Kazmierczak KM, Badal RE, Hackel M, Hoban DJ, Pitout JD.

Emerg Infect Dis. 2014 Nov;20(11):1928-31. doi: 10.3201/eid2011.141388.

39.

Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).

Biedenbach DJ, Bouchillon SK, Hoban DJ, Hackel M, Phuong DM, Nga TT, Phuong NT, Phuong TT, Badal RE.

Diagn Microbiol Infect Dis. 2014 Aug;79(4):463-7. doi: 10.1016/j.diagmicrobio.2014.05.009. Epub 2014 May 17.

PMID:
24923210
40.

Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study.

Biedenbach DJ, Bouchillon SK, Johnson SA, Hoban DJ, Hackel M.

Clin Ther. 2014 Jun 1;36(6):953-60. doi: 10.1016/j.clinthera.2014.04.003. Epub 2014 May 15.

PMID:
24835558
41.

In vitro susceptibility and distribution of beta-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011.

Hoban DJ, Badal R, Bouchillon S, Hackel M, Kazmierczak K, Lascols C, Hawser S.

Diagn Microbiol Infect Dis. 2014 Jul;79(3):367-72. doi: 10.1016/j.diagmicrobio.2014.03.026. Epub 2014 Apr 12.

PMID:
24813688
42.

Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011.

Hawser S, Hoban DJ, Badal RE, Bouchillon SK, Biedenbach D, Hackel M, Morrissey I.

J Chemother. 2015 Feb;27(2):67-73. doi: 10.1179/1973947814Y.0000000164. Epub 2014 Feb 18.

PMID:
24548089
43.

Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.

Morrissey I, Bouchillon SK, Hackel M, Biedenbach DJ, Hawser S, Hoban D, Badal RE.

J Med Microbiol. 2014 Apr;63(Pt 4):556-61. doi: 10.1099/jmm.0.068981-0. Epub 2014 Jan 29.

PMID:
24478449
44.

Molecular epidemiology of Enterobacteriaceae that produce VIMs and IMPs from the SMART surveillance program.

Peirano G, Lascols C, Hackel M, Hoban DJ, Pitout JD.

Diagn Microbiol Infect Dis. 2014 Mar;78(3):277-81. doi: 10.1016/j.diagmicrobio.2013.11.024. Epub 2013 Dec 6.

PMID:
24387958
45.

A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.

Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D.

Pharmaceuticals (Basel). 2013 Nov 1;6(11):1335-46. doi: 10.3390/ph6111335.

46.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA.

J Infect. 2014 Jan;68(1):71-6. doi: 10.1016/j.jinf.2013.09.001. Epub 2013 Sep 7.

PMID:
24016768
47.

Střelná poranění mozku – přehled.

Häckel M.

Rozhl Chir. 2013 Jun;92(6):353-6. Czech. No abstract available.

PMID:
24000473
48.

Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations.

Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J.

Vaccine. 2013 Oct 1;31(42):4881-7. doi: 10.1016/j.vaccine.2013.07.054. Epub 2013 Aug 6.

PMID:
23928466
50.

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010.

Babinchak T, Badal R, Hoban D, Hackel M, Hawser S, Lob S, Bouchillon S.

Diagn Microbiol Infect Dis. 2013 Jul;76(3):379-81. doi: 10.1016/j.diagmicrobio.2013.02.031. Epub 2013 Mar 27.

PMID:
23541118

Supplemental Content

Loading ...
Support Center